Efficacy and Safety of the Modified EPOCH Regimen (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Adult T-cell Leukemia/Lymphoma: A Multicenter Retrospective Study
| Autor: | Yu Yagi, Eriko Nakashima, Motohiko Ikeda, Yoshimichi Tachikawa, Eriko Fujioka, Takamitsu Matsushima, Hayato Utsunomiya, Youko Suehiro, Tatsuro Goto, Akiko Takamatsu, Hiroshi Takatsuki, Hirofumi Ohno, Taisuke Narazaki, Hiroki Muta, Makoto Oyama, Akie Hirata, Mariko Tsuda, Mitsuo Kozuru, Yuji Yufu, Ilseung Choi, Naokuni Uike, Emi Tanaka, Shojiro Haji, Kaname Miyashita, Junichi Kiyasu, Yasuhiro Tsukamoto, Yasuhiro Nakashima |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Cancer Research Vincristine medicine.medical_specialty Gastroenterology Adult T-cell leukemia/lymphoma 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Leukemia-Lymphoma Adult T-Cell EPOCH (chemotherapy) Cyclophosphamide Etoposide Aged Retrospective Studies Aged 80 and over business.industry Hematology Middle Aged medicine.disease Progression-Free Survival Carboplatin Confidence interval Regimen Oncology chemistry Doxorubicin 030220 oncology & carcinogenesis Prednisolone Prednisone Female business 030215 immunology medicine.drug |
| Zdroj: | Clinical Lymphoma Myeloma and Leukemia. 20:e445-e453 |
| ISSN: | 2152-2650 |
| DOI: | 10.1016/j.clml.2020.03.008 |
| Popis: | Background We retrospectively analyzed patients with untreated aggressive adult T-cell leukemia/lymphoma who received the modified EPOCH (mEPOCH) regimen. Patients and Methods Patients received up to 6 mEPOCH cycles. Etoposide (50 mg/m2/day), doxorubicin (10 mg/m2/day), and vincristine (0.4 mg/m2/day) were each given as a continuous 96-hour infusion on days 1 to 4. Prednisolone (40 mg/m2/day) was given intravenously or orally on days 1 to 4 and then tapered and stopped on day 7, and carboplatin (dose calculated for each patient individually using Calvert’s formula according to a target under the curve of 3 mg/mL/min) was given as a 2-hour intravenous infusion on day 6. Results In 103 patients, overall response rate and complete response rate were 58% and 25%, respectively. With a median follow-up of 8.9 months, the median survival time was 9.8 months (95% confidence interval, 7.2-13.9 months). The median progression-free survival (PFS) was 4.2 months (95% confidence interval, 3.4-5.7 months). Patients who completed ≥ 4 cycles experienced significantly better overall survival and PFS compared with those who completed Conclusion The mEPOCH regimen is effective with tolerable adverse effects and may be an alternative treatment option for adult T-cell leukemia/lymphoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect